In The News

February 5, 2018
Immunotherapy: A New Strategy for the Treatment of Cervical Cancer: Interview with Dr. Christian Marth and Dr. Sharad Ghamande
Medical Sciences 2018, 6(1), 9
At the European Gynecological Oncology Congress (ESGO) 2017, held in Vienna, a symposium on immunotherapy took place: A New Strategy for the Treatment of Cervical Cancer, sponsored by Advaxis, Inc.

Dr. Christian Marth, the chair of the symposium, and Dr. Sharad Ghamande, a Gynecological Oncologist coordinating a clinical study of the immunotherapy drug axalimogene filolisbac, shared with us their views about the current state of immunotherapy in cervical cancer.
January 23, 2018
Tolerability of ADXS11-001 Lm-LLO Listeria Based Immunotherapy With Mitomycin, Fluorouracil and Radiation for Anal Cancer
International Journal of Radiation Oncology
ADXS11-0011 Lm-LLO is a live attenuated Listeria monocytogenes (Lm) bacterium bioengineered to secrete the HPV-16 E7 protein fused with a truncated fragment of listeriolysin O (tLLO) that preferentially infects antigen-presenting cells. Exposure to ADXS11-001 may stimulate T-cells to target HPV-transformed cells. The objective of this study was to obtain safety and preliminary efficacy data of the combination of ADXS11-001 with mitomycin, FU and intensity modulated radiation
October 1, 2017
Cancer vaccines, long considered failures, are hot again
MarketWatch
Recent scientific advances and cutting-edge cancer therapies are giving an old idea new life
September 6, 2017
Inside Perspectives: Will Immunotherapy Knock Out Cancer?
WuXi AppTec
The answer is yes, and no. Advances in just the past five years have proven immunotherapy can stimulate the immune system’s natural capabilities to kill cancer cells, and possibly lead to cures for many patients. So yes, it appears immunotherapy is the best weapon yet against cancer and is poised to deliver a knockout blow to this deadly disease.
July 14, 2017
Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11–001
Gynecologic Oncology Research and Practice | BioMed Central
Survival of patients with advanced, recurrent, or metastatic human papillomavirus (HPV)-associated cancer is suboptimal despite the availability of various treatment modalities. The recently developed bacterial vector Listeria monocytogenes (Lm) activates innate and adaptive immune responses and is expected to offer immunologic advantages.
June 29, 2017
Blood Protein Levels May Predict Cervical Cancer Patients Likely to Benefit from Advaxis’ Immunotherapy
Immuno-Oncology News
Measuring the blood levels of certain proteins before treatment may help identify patients more likely to benefit from Advaxis‘ immunotherapy vaccine candidate axalimogene filolisbac (axal).
June 15, 2017
Chris Duke: Fighting the Battle Against Cervical Cancer
Latino Leaders
Annually, more than 500,00 women are diagnosed with cervical cancer globally and at any time, there are approximately 2.5M women living with the disease. Despite the availability of vaccines against HPV which make HPV-related cancers almost entirely preventable, more than 13,000 women in the US alone are diagnosed annually with cervical cancer and 4,200 women will succumb to the disease. The incidence of cervical cancer for Latina women in the United States is highest amongst all racial/ethnic
June 14, 2017
What is Lm Technology? (VIDEO)
OncologyTube
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. gives an overview of Advaxis' Lm Technology™, which alters Listeria monocytogenes (Lm) bacteria to stimulate cancer-fighting T-cells directed against cancer antigens. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
June 14, 2017
Advaxis’ Preclinical Neoantigen Technology (ADXS-NEO) (VIDEO)
OncologyTube
Robert Petit, MD, Chief Scientific Officer of Advaxis, Inc. discusses the NEO program which is a collaboration between Amgen and Advaxis that is designed to activate a patient's immune system to respond to certain mutations in the tumors. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
June 13, 2017
AIM2CERV: Identifying Patients with High Risk for Recurring Disease in Cervical Cancer (VIDEO)
OncologyTube
Sharad A. Ghamande, MD of Medical College of Georgia discusses the unmet need for cervical cancer and the promising data coming out of the AIM2CERV trial, especially for patients with high risk of recurring disease. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
June 3, 2017
Overcoming Challenges of the AIM2CERV Trial (VIDEO)
OncologyTube
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the challenges of the AIM2CERV trial at the 2017 ASCO Annual Meeting in Chicago, IL.
June 2, 2017
Use of Axalimogene Filolisbac for Treatment of HPV-Associated Cancers (VIDEO)
OncologyTube
Brian Slomovitz, MD of University of Miami Health System and Sylvester Comprehensive Cancer Center discusses the use of AIM2CERV's axalimogene filolisbac for the treatment of HPV-associated cancers, including cervical cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
June 2, 2017
Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy
Gynecologic Oncology Research and Practice | BioMed Central
Immune responses to the facultative intracellular bacterium Listeria monocytogenes (Lm) are robust and well characterized. Utilized for decades as a model of host-disease immunology, Lm is well suited for use as an immunotherapeutic bacterial vector for the delivery of foreign antigen
May 10, 2017
Erin Andrews, the Dancing with the Stars Host, Will Be Special Guest at Cervical Cancer Forum
Cervical Cancer News
Erin Andrews, a cervical cancer survivor who is the host of ABC Television’s “Dancing with the Stars” program, will be a special guest at the Advaxis-sponsored Cervical Cancer Educational Forum in Hollywood, Florida, May 18.
May 3, 2017
JENNIE: Preventing and treating gynecologic cancers (VIDEO)
JENNIE Show | WJBF
We begin today with a subject that is really important for women, because all of us are at risk for gynecologic cancers, and that risk increases with age. When gynecologic cancers are found early, treatment is most effective.

Investor Relations

In the News